Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
All edits
Edits on 13 Jan, 2024
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+478 characters)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Article
Study summary
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.
Infobox
Is a
NCT Number
Trial Recruitment Size
1920
Trial Sponsor
Clinical Trial Start Date
June 21, 2021
0Primary Completion Date
January 19, 2023
0Study Completion Date
January 19, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Official Website
Official Name
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers0
Last Updated
January 30, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Find more entities like Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.